Skip to content

Study · Observational study · 2013

1 result

[Prognosis of cognitive deficit progression in aged patients with mild cognitive impairment under prolonged therapy (a three year observation)].

Gavrilova SI, Kolykhalov IV, Fedorova IaB, Kalyn IaB, Selezneva ND, Samorodov AV, Miasoedov SN, Boksha IS

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2013Cited by 1 (Europe PMC)

PMID23612410 (opens in a new tab)PepBankPUB-23612410
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In a subgroup of patients with amnestic MCI receiving cerebrolysin, fast cognitive decline indicated low treatment efficacy.

    In plain wordsIn a subgroup with mild cognitive impairment, cognitive function declined rapidly during cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedFast cognitive decline in dementia risk subgroup
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    A "dementia risk group" with fast cognitive decline (i.e. the low efficacy of the treatment) was identified.
    1 context sentence
    Summary · context
    Patients with amnestic MCI (n=53) were treated with cerebrolysin for three years and underwent regularly neurocognitive and clinical psychiatric tests.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.